Education
About Us
Working with TipRanks
Follow Us
NextCell Pharma AB (DE:65G)
FRANKFURT:65G
65G Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.06 - €0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.12M
Enterprise ValueN/A
Total Cash (Recent Filing)€26.34M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Jul 24, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding73,091,324
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
65G FAQ
What was NextCell Pharma AB’s price range in the past 12 months?
NextCell Pharma AB lowest stock price was €0.06 and its highest was €0.29 in the past 12 months.
What is NextCell Pharma AB’s market cap?
NextCell Pharma AB’s market cap is €7.12M.
When is NextCell Pharma AB’s upcoming earnings report date?
NextCell Pharma AB’s upcoming earnings report date is Jul 24, 2025 which is in 63 days.
How were NextCell Pharma AB’s earnings last quarter?
NextCell Pharma AB released its earnings results on Apr 25, 2025. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.027.
Is NextCell Pharma AB overvalued?
According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued.
Does NextCell Pharma AB pay dividends?
NextCell Pharma AB does not currently pay dividends.
What is NextCell Pharma AB’s EPS estimate?
NextCell Pharma AB’s EPS estimate is -0.02.
How many shares outstanding does NextCell Pharma AB have?
NextCell Pharma AB has 73,091,324 shares outstanding.
What happened to NextCell Pharma AB’s price movement after its last earnings report?
NextCell Pharma AB reported an EPS of -€0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of NextCell Pharma AB?
Currently, no hedge funds are holding shares in DE:65G
Company Description
NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
Technical Analysis
Xintela AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―